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Erika Salvi,2 Roberto Eleopra1 and Giuseppe Lauria2,3
The diagnostic criteria for small fibre neuropathy are not established, influencing the approach to patients in clinical practice, their
access to disease-modifying and symptomatic treatments, the use of healthcare resources, and the design of clinical trials. To
address these issues, we performed a reappraisal study of 150 patients with sensory neuropathy and a prospective and follow-up
validation study of 352 new subjects with suspected sensory neuropathy. Small fibre neuropathy diagnostic criteria were based on
deep clinical phenotyping, quantitative sensory testing (QST) and intraepidermal nerve fibre density (IENFD). Small fibre neur-
opathy was ruled out in 5 of 150 patients (3.3%) of the reappraisal study. Small fibre neuropathy was diagnosed at baseline of the
validation study in 149 of 352 patients (42.4%) based on the combination between two clinical signs and abnormal QST and
IENFD (69.1%), abnormal QST alone (5.4%), or abnormal IENFD alone (20.1%). Eight patients (5.4%) had abnormal QST and
IENFD but no clinical signs. Further, 38 patients complained of sensory symptoms but showed no clinical signs. Of those, 34
(89.4%) had normal QST and IENFD, 4 (10.5%) had abnormal QST and normal IENFD, and none had abnormal IENFD alone.
At 18-month follow-up, 19 of them (56%) reported the complete recovery of symptoms and showed normal clinical, QST and
IENFD findings. None of those with one single abnormal test (QST or IENFD) developed clinical signs or showed abnormal
findings on the other test. Conversely, all eight patients with abnormal QST and IENFD at baseline developed clinical signs at
follow-up. The combination of clinical signs and abnormal QST and/or IENFD findings can more reliably lead to the diagnosis of
small fibre neuropathy than the combination of abnormal QST and IENFD findings in the absence of clinical signs. Sensory
symptoms alone should not be considered a reliable screening feature. Our findings demonstrate that the combined clinical,
functional and structural approach to the diagnosis of small fibre neuropathy is reliable and relevant both for clinical practice
and clinical trial design.
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Introduction
Small fibre neuropathy (SFN) is a sensory, typically painful,
disease of thin myelinated and unmyelinated nerve fibres. It
occurs early in the course of several systemic illnesses such
as diabetes, amyloidosis and connective tissue disorders,
can be genetically determined or idiopathic (Cazzato and
Lauria, 2017), and is a model to investigate the efficacy of
new targeted analgesics (Eijkenboom et al., 2019b). The
somatic compartment of this class of fibres conveys thermo-
sensation, nociception and itch from cutaneous fields
through sensory peripheral nerves to the dorsal horns in
a hierarchical fashion determined by molecular-driven
coding of sensory neurons (Lallemend and Ernfors, 2012;
LaMotte et al., 2014; Lou et al., 2015). Distinct molecular
profiles have been identified as key for the neurogenesis of
nociceptors (Bartesaghi et al., 2019) and axon ending tar-
geting to the ectodermic or mesodermic/endodermic tissues
(Yang et al., 2013). Thus, phylogenetically conserved
peripheral signalling such as thermosensation and nocicep-
tion are conveyed towards the integrative brain areas
through a complex class of nerve fibres whose function is
driven by precise molecular ontogenesis.
Somatic and autonomic functional assessment of small
nerve fibres is achieved by assaying the psychophysical sen-
sory thresholds (e.g. cold, heat) by quantitative sensory
testing (QST), pain-related and laser evoked potential re-
cording, single axon recording using microneurography and
tests encompassing sympathetic and parasympathetic auto-
nomic functions (Terkelsen et al., 2017). Their structural
assessment relies on skin biopsy and corneal confocal mi-
croscopy. The first combines quantification of intraepider-
mal nerve fibre density (IENFD), dermal nerve bundles, and
autonomic organ innervation with analysis of pain-related
receptors and myelin protein expression, and has become a
routine method (Lauria et al., 2004, 2006, 2011; Lauria
and Lombardi, 2007; Provitera et al., 2007; Zhao et al.,
2008; Gibbons et al., 2009; Nolano et al., 2010). The
second provides various morphometric parameters to quan-
tify corneal nociceptors and their changes over time, and is
currently mostly applied in research (Kalteniece et al.,
2018; Petropoulos et al., 2019). Overall, these techniques
have replaced sensory nerve biopsy that, although it allows
identification of small nerve fibres enwrapped into Remak
bundles in semi-thin sections, and their ultrastructural
quantification, it cannot differentiate afferent and efferent
autonomic from somatic axons and is much more invasive
(Sommer, 2018).
Despite the advances allowed by new techniques, the
diagnostic criteria for SFN are yet to be fully established
(Terkelsen et al., 2017). This limitation has several impli-
cations both for clinical practice in terms of correct access
of patients to treatments and research for the definition of
entry criteria in trials. However, it does not arise from the
lack of knowledge on the diagnostic performance of tests
for small nerve fibre functioning or morphometric assay,
but rather from how their combination meets the diagnos-
tic requirements for individual patients at the clinical level.
Indeed, abnormal findings in some small nerve fibre-related
tests, such as skin biopsy, QST or laser-evoked potentials
can occur in painful clinical conditions irrespective of the
localization, nature and aetiology of pain (Devigili et al.,
2008; Backonja et al., 2013; Terkelsen et al., 2017; Uceyler
et al., 2018) and even in painless neuropathies or systemic
diseases (Nolano et al., 2001, 2008; Bennett and Woods,
2014; Dalla Bella et al., 2016; Marchi et al., 2018). In such
a frame, patients’ symptoms and signs of small nerve fibre
dysfunction are crucial to the reliable interpretation of the
findings obtained by the diagnostic tests.
In the past decade, two sets of diagnostic criteria have
been proposed. The first (Besta criteria) (Devigili et al.,
2008) is based on the combination of at least two abnor-
mal findings of the following: (i) clinical signs of small fibre
impairment (pinprick and thermal sensory loss and/or allo-
dynia and/or hyperalgesia); (ii) abnormal warm or cold
thresholds, or both, at the foot as assessed by QST; and
(iii) reduced IENFD at the distal leg. Exclusion criteria were
any clinical sign of large fibre impairment (e.g. light touch
and vibratory sensation, deep tendon reflexes, limb or gait
ataxia) and any abnormality at nerve conduction studies
(NCSs). The second, within the revised guideline of the
Diabetic Neuropathy Study Group of the European
Association for the Study of Diabetes (NEURODIAB)
(Tesfaye et al., 2010) based on a grading as: (i) possible,
if symptoms or clinical signs of small fibre damage, or
both; (ii) probable, if clinical signs of small fibre damage,
and normal sural NCS; and (iii) definite, if clinical signs of
small fibre damage, normal sural NCS, and abnormal QST
thresholds at the foot or reduced IENFD at the ankle, or
both. The NEURODIAB criteria do not require specifica-
tion of the clinical signs of small fibre damage.
Our study aimed to address three key questions: (i) the
agreement between the two proposed criteria; (ii) the
weight of each of the three main components of the pro-
posed criteria, i.e. symptoms and signs (clinical), QST
(functional), and IENFD (structural); and (iii) the most re-
liable approach to individual patients suspected to have
SFN. To this end, based on the comparison between the
NEURODIAB and Besta criteria, we performed a re-
appraisal study of a cohort of sensory neuropathy patients
(Devigili et al., 2008), analysed how patients were reclassi-
fied, and conducted a prospective and follow-up validation
study on a new large cohort of patients to confirm the
reliability of the diagnostic criteria.
Materials and methods
Part 1 Reappraisal study
We retrospectively re-evaluated the clinical files of 150 sensory
neuropathy patients included in the study performed to de-
velop the Besta criteria (Devigili et al., 2008). For all, we
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reassigned the value of IENFD at the distal leg using the nor-
mative values (Lauria et al., 2010a), which were not available
at the time the study was carried out. The diagnosis of definite
SFN based on the NEURODIAB criteria (Tesfaye et al., 2010)
was used as the gold standard to reclassify the SFN patients
formerly diagnosed using the Besta criteria. Thereafter, we
compared the diagnostic power between skin biopsy and
warm detection QST thresholds at foot and hand between
the two groups of definite SFN based both on Besta and
NEURODIAB criteria. Data from 99 age and sex-matched
healthy subjects were used as controls for the QST findings.
Part 2 Validation study
We conducted a prospective and follow-up study on new pa-
tients referred to our centre for suspected sensory neuropathy
between January 2009 and September 2017. The study was
designed according to the standards for reporting of diagnostic
accuracy (STARD) and approved by the local Ethic
Committee. All patients underwent a standardized protocol
comprehensive of questionnaires and pain maps, clinical and
neurophysiological tests, multimodal QST battery and skin
biopsy, as detailed below. Inclusion criteria were age 418
years and symptoms suggesting sensory peripheral neuropathy
(positive and/or negative symptoms with length-dependent dis-
tribution at lower limbs and autonomic symptoms) not other-
wise explained.
Clinical evaluation and questionnaires
From all patients, we recorded a detailed clinical history
including time and features of symptoms onset and any con-
dition potentially causing neuropathy (e.g. known systemic dis-
eases, neurotoxic drugs, etc.). Baseline screening included
haematological assays for diabetes and impaired glucose toler-
ance, thyroid diseases, vitamin B12 and folate, hepatitis C and
HIV makers, autoantibodies, serum and urine protein immu-
nofixation, antibodies against gangliosides and sulphatide,
onconeuronal antibodies and neoplastic markers.
Patients were asked to report any type of annoying or pain-
ful sensation either spontaneous (e.g. paraesthesia, cold or
warm feeling, tightening feeling, cramps) or evoked (e.g. touch-
ing the sheets, warm or cold water, wearing shoes, walking).
As part of the baseline evaluation, all patients were asked to
fill the SFN Symptom Inventory Questionnaire (SFN-SIQ)
(Bakkers et al., 2014) for somatic and autonomic symptoms
recording and the Neuropathic Pain Symptoms Inventory
(NPSI) questionnaire (Padua et al., 2009), and to draw their
pain distribution on a picture of a human.
All patients underwent a thorough bedside clinical evalu-
ation. Presence and distribution of negative and positive sen-
sory and signs were recorded using a comparative assessment
of affected and non-affected skin areas to differentiate the
quality of the altered sensation and define dermatomeric,
mono/multineuropathic and polyneuropathic distribution.
Vibratory sensation was quantified using the 128 Hz gradu-
ated tuning fork (Martina et al., 1998). Cutaneous sensory
signs were assessed asking the patient to keep the eyes closed
and to report the sensation induced by tactile stimuli and
gently brushing with cotton bud and flat tip brush (dynamic
allodynia), punctate skin stimulation with a stick or pin (punc-
tate allodynia), prickling with disposable needle (hyperalgesia),
cooling/warming with cold/warm water tube (thermal allody-
nia), superficial and deep mechanical sensation by finger pres-
sure applied to skin and underlying tissue (static allodynia and
hyperalgesia) (Jensen and Finnerup, 2014). The feeling of dis-
torted sensation (e.g. spreading, increased and/or persistent,
electric shock) in the affected areas (e.g. soles, dorsal feet,
legs, fingertips, palms, forearms, peri-nipple) compared with
the neat (normal) sensation in non-affected areas were re-
corded as allodynia, hyperalgesia or aftersensation based on
the type of stimulus used (Backonja et al., 2013). Each clinical
test was performed at least twice. Sensory signs were graded
as + 2, + 1 (gain of function), 0, 1, 2 (loss of function) to
allow the comparison with QST findings. Signs of dysautono-
mia were also recorded (e.g. pupil abnormalities, abnormal
sweating, skin flushing or discolouration, orthostatic hypoten-
sion, heart frequency).
Nerve conduction studies
Sensory and motor NCSs were performed using surface re-
cording electrodes with standard placement. Compound
muscle action potential, motor nerve conduction velocity,
distal motor latency and F-wave latencies were recorded for
ulnar, peroneal, and tibial nerves bilaterally. Sensory nerve
conduction velocity and sensory nerve action potential were
assessed for radial, median, ulnar, superficial peroneus, sural
nerves and sural dorsal nerves.
Skin biopsy
All patients underwent skin biopsies at distal leg and proximal
thigh according to standardized procedures for bright-field
immunohistochemistry (Lauria et al., 2010c). IENFD was
quantified according to standardized guidelines and individual
reports based on age and sex-adjusted normative values
(Lauria et al., 2010b).
Quantitative Sensory Testing
QST examination was performed with a comprehensive
method of threshold determination and a multimodal ap-
proach including thermal and mechanical stimuli, in order to
improve the sensitivity. Stimuli were tested bilaterally to cor-
rect borderline findings.
Warm and cold detection thresholds (WDT, CDT) were
assayed combining limits and levels methods (LIM+LEV) at
the dorsal foot bilaterally and at the dorsal aspect of the non-
dominant hand. Then, the limits method (LIM) was used alone
for WDT and CDT at proximal thigh, and for cold and heat
pain threshold determination at all the sites. Abnormal sensa-
tions including errata sensation, thermal allodynia or hyper-
algesia, and aftersensation were recorded for all the tests. The
sites were evaluated in the following order: non-dominant
dorsal hand, right dorsal foot, proximal thigh and left dorsal
foot. Thermal stimuli were assessed by the MedocTM device
(MedocTM Thermal Sensory Analyser, TSA-2001) using a 30
 30 mm probe, with ramp stimuli of 1C/s from 32C.
Results were compared with published reference normative
values (Magerl et al., 2010) and for direct comparison with
a cohort of 99 age- and gender-matched healthy subjects who
underwent the same QST protocol. We used as cut-off Z-
values above + 1.96 or below 1.96.
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Mechanical detection threshold was measured with a stan-
dardized set of modified von Frey hairs (SenseLab, Somedic
von Frey Aesthesiometer; range 0.26–490 mN) using the
method of limits in five determinations. The test was con-
ducted at all the sites where thermal stimuli were tested.
Statistical analysis
We used the unpaired t-test and the Mann-Whitney test to
compare the normally and the non-normally distributed vari-
ables, respectively. Patient categorization based on clinical
variables was correlated with thermal thresholds (WDT and
CDT) at both feet, and IENFD at the distal leg.
Sensory modalities assessed by the clinical exam and graded
as mentioned above and QST findings were compared using
the paired t-test and Pearson R2 coefficient test. We used the
Spearman’s rank correlation coefficient for the correlation ana-
lysis between clinical and laboratory variables. Where applic-
able P 5 0.05 was considered statistically significant. For
logistic regression studies we used the group of definite SFN
from the reclassification study as the validation gold standard
to be compared with healthy subjects group. Receiver operat-
ing characteristic (ROC) curves were built for distal leg IENFD
and several combinations of thermal QST at foot i.e. WDT by
method of limits unilaterally (WDT LIM foot) or bilaterally
(WDT LIM R+L), WDT by method of levels unilaterally
(WDT LEV foot) or bilaterally (WDT LEV R+L), WDT com-
bined with CDT by method of levels (WDT+CDT LEV) and
limits (WDT+CDT LIM). Sensitivity, specificity and diagnostic
accuracy were calculated by ROC findings for the different
techniques, including combination of modality for thermal
thresholds detection. There were no missing data in either
the reappraisal or validation studies. All analyses were per-
formed using the SPSS for Mac release, 21.0.0.0.
Data availability
The data that support the findings of this study are available
from the corresponding author.
Results
Part 1 Reappraisal study
The assignment of IENFD values based on the normative
study (Lauria et al., 2010a) changed the diagnosis in 5 of
150 patients: SFN was ruled out in one patient, whereas
four mixed (large and small sensory fibre) neuropathies
were reclassified as large fibre neuropathy. Based on the
Besta criteria, 25 of 66 patients eventually diagnosed with
definite SFN had abnormal IENFD and QST findings but
lacked clinical signs showing only one of the two negative
sensory signs required (i.e. pinprick and thermal hypoesthe-
sia). Conversely, the NEURODIAB criteria for definite SFN
require the evidence of ‘clinical signs of small fibre
damage’, without further specification in number and qual-
ity. Therefore, when we compared the reliability of the
Besta criteria for definite SFN against the NEURODIAB
criteria used as the gold standard, all except one patient
met the criteria. The ROC analysis for diagnostic efficacy
of the Besta criteria based on the comparison with the
NEURODIAB showed an area under the curve (AUC) of
0.98, with 100% sensitivity and 98.5% specificity.
Part 2 Validation study
A total of 352 patients (184 females and 168 males) met
the entry criteria. Ten patients were diagnosed with vascu-
lar stenosis, somatoform disorder, lumbar stenosis, plantar
fasciitis and ruled out. Sensory neuropathy was hypothe-
sized in 342 patients (176 females and 166 males; age
range 19–79 years, mean 58  13.3) complaining of symp-
toms. All patients underwent clinical, neurophysiological,
QST, skin biopsy, and laboratory tests. The diagnostic clas-
sification was axonal large sensory fibre neuropathy (43;
12.6%), mixed large and small sensory fibre neuropathy
(81; 23.7%), sensory neuronopathy (16; 4.7%), demyeli-
nating neuropathy (5; 1.5%), mononeuropathy (3; 0.8%),
and multiplex mononeuropathy (7; 2%).
The remaining 187 patients with no clinical and NCS
evidence of large sensory and motor nerve fibre impairment
were considered affected by possible SFN. Of those, 38
(20.3%; 29 females, nine males; mean age 45.6  11.9)
complained of sensory symptoms but did not show any
clinical signs. Thirty-four (89.4%) had normal QST and
IENFD, four (10.5%) had abnormal QST and normal
IENFD, and none had abnormal IENFD only. Eventually,
using the Besta criteria, 149 patients were diagnosed with
definite SFN based on the combination of two clinical signs
plus abnormal QST and IENFD (103; 69.1%), or abnor-
mal QST alone (8; 5.4%), or abnormal IENFD alone (30;
20.1%), whereas eight patients (5.4%) did not present clin-
ical signs but had abnormal QST and IENFD. This latter
subgroup of patients would have been ruled out based on
the NEURODIAB criteria that require the evidence of clin-
ical signs.
We compared the diagnostic efficiencies of the
NEURODIAB criteria and the Besta criteria. To this end,
diagnostic efficiency was calculated using the Besta criteria
as the gold standard, which identified a group of true
positive patients (n = 149). The diagnosis of definite SFN
had a sensitivity of 94.6%, specificity of 99% [95% confi-
dence interval (CI) = 0.649–0.775]; positive predictive
value (PPV) 0.993 (95% CI 0.97–0.99), negative predictive
value (NPV) 0.925 (95% CI 0.882–0.953). For the diagno-
sis of probable SFN, values did not differ from those of
definite SFN because in this cohort no patient had negative
signs alone without abnormal QST and/or IENFD findings.
The diagnosis of possible SFN had sensitivity 100% (all
187 patients had symptoms of SFN and normal NCS), spe-
cificity 71.5% (95% CI 0.965–0.998), PPV 0.793 (95% CI
0.74–0.837) and NPV 1.0 (95% CI 0.98–1.0).
Sensory symptoms were reported to have unilateral onset
in 69 patients (46.3%), whereas 38 (25.5%) described their
complaints as asymmetric at the neurological examination.
We recorded autonomic symptoms in 52 patients (34.9%)
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using the SFN-SIQ (Bakkers et al., 2014). The NPSI ques-
tionnaire (Padua et al., 2009) findings are summarized in
Table 1.
One hundred and eleven patients showed both negative
and positive signs, whereas 30 patients had only negative
signs (Table 2). In 79 patients there were signs of periph-
eral venous-arteriolar dysfunction, including erythromelal-
gia-like in 22 patients. The aetiology of SFN was identified
in 87 patients (58.3%), whereas it remained unknown in
62 patients. Aetiologies included diabetes (22; 25.4%), im-
paired glucose tolerance (26; 29.9%), mixed connective
tissue disease (17; 19.5%), hypothyroidism (6; 6.9%), sar-
coidosis (2; 2.3%), Fabry disease (6; 6.9%), rheumatoid
arthritis (2; 2.3%), progressive systemic sclerosis (2;
2.3%), Sjo¨gren syndrome (2; 2.3%), HCV infection (1;
1.1%) and Borrelia burgdorferi infection (1; 1.1%).
Diagnostic accuracy and comparison
studies
Table 3 details sensitivity, specificity and diagnostic effi-
ciency in the 149 SFN patients. ROC analysis showed a
higher performance of IENFD compared to QST.
Moreover, it showed that QST achieved the highest per-
formance when both warm and cold thresholds were per-
formed at the feet using with both limit and level test. The
comparison between clinically determined positive and
negative signs and QST Z-scores showed good agreement
for all the sensory modalities tested: warm (r2 = 0.91), cold
(r2 = 0.68), mechanical (r2 = 0.73) and pressure sensation
(r2 = 0.81).
Follow-up study
Over a period of 2.6 1.4 years, we followed up 104 of
149 patients with definite SFN, 54 of them with unknown
aetiology, and all 38 patients with symptoms but no clinical
signs of SFN (Fig. 1). All patients underwent haematolo-
gical screening, clinical evaluation with SIQ-SFN and NPSI,
QST, NCS, and/or other instrumental evaluation when clin-
ically appropriate.
In 28 of 104 SFN patients, abnormal findings at NCS
changed the diagnosis of SFN in mixed large and small
fibre neuropathy. SFN remained idiopathic in 40 of 54 pa-
tients (74%), whereas 12 patients (22%) were diagnosed
with impaired glucose tolerance (4), hypothyroidism (4),
coeliac disease (3) and diabetes (1). The pair sample t-test
did not show significant changes in the pain scales and
NPSI findings. Follow-up skin biopsy was performed in
62 of 104 patients and showed a mean loss of 1.23
fibres/mm yearly.
At 18-month follow-up (range 1–6 years), 19 of 34
(56%) patients with symptoms alone reported complete re-
covery and had normal clinical examination, QST and
IENFD. In 14 of them an alternative diagnosis was
achieved (e.g. foot osteoarthritis, chronic venous insuffi-
ciency). Of the three of the four patients with symptoms
and abnormal QST alone at baseline, none showed clinical
signs or abnormal IENFD. All eight patients diagnosed
Table 1 Intensity and frequency of pain features in 149
small fibre neuropathy patients using the NPSI
questionnaire
Painful symptoms Patients, n (%) Mean NRS 11
point
Spontaneous pain 56 (39.7) 6.6
Evoked pain 21 (14.9) 6.2
Spontaneous and evoked pain 64 (45.3) 8.6
Main quality of pain
Burning pain 71.9 (51) 6.5
Sharp pain 31.0 (22) 7.8
Deep aching pain 15.5 (11) 7.3
Pinprick 14.1 (10) 5.8
Cold pain 4.2 (3) 6.9
Itching 4.2 (3) 8.5
Frequency of pain features at NPSI
Q1 Burning 102 (72.3) 5.0  1.7
Q2 Squeezing 75 (51.0) 4.1  2.3
Q3 Pressure 69 (48.9) 3.6  1.0
Q4 Electric shocks 11 (7.8) 1.6  2.1
Q5 Stabbing 42 (29.8) 1.7  2.0
Q6 Evoked by brushing 52 (36.9) 3.2  2.4
Q7 Evoked by pressure 47 (33.3) 2.8  2.4
Q8 Evoked by cold stimuli 39 (27.7) 1.6  2.0
Q9 Pins and needles 71 (50.3) 4.7  1.6
Q10 Tingling 18 (12.8) 2.4  2.1
NPSI = Neuropathic Pain Symptoms Inventory.
Table 2 Negative and positive sensory signs in 141 pa-
tients with SFN
Patients,
n (%)
Stimulus
Negative signs
Total 141
Pinprick and thermal
hypoaesthesia
141 (100) Disposable needle;
cold/warm
water tube
Mechanical hypoaesthesia 31 (22) Cotton ball
Positive signs
Total 111 (78.7)
Allodynia
Mechanical – punctate (static) 69 (62) Stick or pin
Mechanical (dynamic) 46 (41.4) Flat tip painter’s brush
Thermal 55 (49.5) Cold/warm water tube
Pressure 66 (59.4) Gentle finger pressure
Hyperalgesia
Pinprick hyperalgesia 91 (82) Disposable needle
Pressure-evoked hyperalgesia 79 (71) Finger pressure
Aftersensation 88 (79)
In 111 patients we found both negative and positive signs, whereas 30 patients had only
negative signs.
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with definite SFN based on abnormal QST and IENFD
alone showed clinical signs.
Discussion
SFN is an emergent, intriguing disorder with relevant
impact on patients’ well-being and research in neuropathic
pain (Terkelsen et al., 2017). Small nerve fibres are the
largest class of peripheral nerves in mammals and encom-
pass highly conserved functions in the domain of thermo-
sensation, nociception and autonomic responses. Their
endings in epidermis and epithelia widely express the
TRPV1 receptor and are the most distal peripheral nocicep-
tors in humans (Lauria et al., 2005, 2006). The reason why
they can selectively degenerate and sometimes cause
Figure 1 Flow-chart of the diagnostic assessment of patients included in the validation study.
Table 3 Diagnostic accuracy using of skin biopsy and various combination of thermal thresholds test comparing SFN
and healthy subjects
AUC ROC Sensitivity Specificity Efficiency
IENF density distal leg 0.93 94.3 91.9 93.3
Thermal QST combination
Method of limits
WDT foot LIM 0.606 73.7 50.5 64.2
WDT feet LIM R + L 0.76 75.1 74.7 75
Method of levels
WDT foot LEV 0.716 67.3 78.7 72
WDT feet LEV R + L 0.809 78.7 78.8 78.7
WDT + CDT feet (LEV) 0.783 85.8 76.7 82.8
Method of limits and levels combined
WDT + CDT feet (LIM + LEV) 0.836 85.1 80.8 82.9%
L = left; LEV = levels; LIM = limits; R = right.
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neuropathic pain is largely unknown. Indeed, they also de-
generate in painless conditions such as amyotrophic lateral
sclerosis (Weis et al., 2011; Dalla Bella et al., 2016) in
which a potential mechanism has been discovered in the
SODG93A mouse model to be the accumulation of a toxic
splicing variant of peripherin that is not expressed in large
size sensory neurons (Sassone et al., 2016).
The assessment of small fibre nerves should be in the
frame of a well-defined clinical context (Cazzato and
Lauria, 2017). The early diagnosis of SFN is important to
identify patients at risk of developing more generalized
neuropathy such as that associated with amyloidosis
(Chao et al., 2019) and diabetes (Lauria et al., 2003;
Devigili et al., 2008; Khoshnoodi et al., 2016; Loseth
et al., 2016). The recent identification of sodium channel
gene mutations in idiopathic and diabetic SFN patients
(Huang et al., 2014; Waxman et al., 2014; Alsaloum
et al., 2019; Eijkenboom et al., 2019a) has enlarged the
spectrum of neuropathic pain disorders including new
phenotypes (Faber et al., 2012a, b; Hoeijmakers et al.,
2012; Bennett and Woods, 2014; Devigili et al., 2014;
Serra et al., 2014; Doppler et al., 2015; Martinelli-
Boneschi et al., 2017), allowing the development of new
innovative in vitro (Persson et al., 2013; Rolyan et al.,
2016) and in vivo (Eijkenboom et al., 2019b) models,
and has prompted randomized clinical trials with new tar-
geted compounds. In this scenario, the need for clearly
defined and reliable diagnostic criteria for SFN appears
crucial (Terkelsen et al., 2017).
The combination of various somatic and autonomic
nerve testing has been proposed to increase the diagnostic
ability (Terkelsen et al., 2017) but none of them has been
validated or concretely applied in clinical practice. As a
matter of fact, the process toward the definition of the
diagnosis of SFN in individual patients, which begins
from complaints of sensory symptoms, is based on clues
from skin biopsy and/or QST results, whose reliability
has been investigated in a huge number of studies
(Gasparotti et al., 2017). Conversely, the weight of the
clinical signs, albeit emphasized (Tesfaye et al., 2010;
Malik et al., 2011; Edwards et al., 2016), remains unad-
dressed, as they are felt to be difficult to analyse objectively
at the bedside. Specific questionnaires such as the Utah
Early Neuropathy Scale can be used to detect subtle sen-
sory disturbances (Singleton et al., 2008) and could differ-
entiate patients with neuropathy from controls (Zilliox et
al., 2015), but they have not been included in guidelines
and recommendations, and only one study has tested spe-
cificity and sensitivity of the clinical examination (Devigili
et al., 2008).
The aim of this work was to provide conclusive evidence
on the diagnostic criteria for SFN to be used in clinical
practice and trial design. One challenging issue regards
the potential circularity of the analysis of efficacy of three
approaches used to achieve the diagnosis, namely clinical
examination, IENFD and QST findings. Acknowledging the
lack of a ‘gold standard’ with which to compare specificity
and sensitivity of the diagnostic criteria, we first proposed
the ‘two of three’ combinatory approach (Devigili et al.,
2008). The ‘Besta criteria’ are based on the evidence of at
least two abnormal findings among the three used to assess
small fibre damage, which include the presence of two
negative clinical signs (pinprick and thermal sensory loss)
possibly associated with positive clinical signs (allodynia
and/or hyperalgesia), abnormal warm or cold thresholds,
or both, at the foot assessed by QST, and reduced
IENFD at the distal leg. To confirm the validity of our
criteria, we performed a reappraisal and a validation
study keeping as ‘gold standard’ the NEURODIAB criteria
that essentially define the diagnosis of SFN in the presence
of the combination of clinical signs not further specified
and abnormal QST or reduced IENFD at the distal leg.
Our results showed not only a strict agreement between
the two diagnostic approaches, but demonstrated the val-
idity of the clinical assessment both for negative and posi-
tive signs when compared with the QST findings, indicating
the reliability of focused bedside assessment of small fibre
functioning in individual patients. These findings could
contribute in better defining the clinical profile of patient’s
phenotype (von Hehn et al., 2012) and meeting the needs
of clinical trial design (Farrar, 2010).
Sensory symptoms, most commonly spontaneous and
positive thus in the spectrum of neuropathic pain, are the
reason why patients seek help and neurologists schedule
investigations for possible neuropathy. Nevertheless, sen-
sory symptoms belong to a completely subjective domain
and their reliability cannot be directly tested. To overcome
this issue, we separately analysed the course of 38 of 187
patients presenting with symptoms but showing no clinical
signs at the neurological examination (Fig. 1). In 89.5% of
them, QST and IENFD both at baseline and 18-month
follow-up were normal, whereas in the remaining 10.5%
abnormal QST thresholds remained the unique finding.
QST remains a valid test to assess the diagnosis of SFN,
though its diagnostic accuracy is lower than that of IENFD
(Table 3). Our study demonstrated that its specificity and
sensitivity increases if warm and cold thresholds are mea-
sured combining the methods of limits and levels at both
the feet. However, such comprehensive testing is extremely
time consuming and the determination of warm threshold
alone using the method of levels could be a reasonable
compromise.
In conclusion, to increase the reliability of the diagnosis
and reduce the number of screening failure in clinical trials,
patients should be suspected to have SFN when at least two
clinical signs are present. Sensory symptoms alone are not
reliable. Quantification of IENFD remains the most reliable
tool to confirm the diagnosis.
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